Cramer Rosenthal McGlynn’s Integra LifeSciences IART Stock Holding History

Cramer Rosenthal McGlynn’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-309,525	Closed	-$8.52M	–	243
2015 Q2	$8.52M	Sell	309,525 -182,032	-37%	-$4.85M	0.11%	172
2015 Q1	$12.4M	Buy	491,557 +78,226	+19%	+$1.85M	0.14%	165
2014 Q4	$9.16M	Buy	+413,331	New	+$8.38M	0.09%	163

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cramer Rosenthal McGlynn's IART Position: Q3 2015 in Review

Cramer Rosenthal McGlynn sold out of Integra LifeSciences (IART) in Q3 2015, closing a stake of 309,525 shares — an estimated $8.52M sold.

Cramer Rosenthal McGlynn first reported a position in IART in Q4 2014 and held it in 3 quarters. The position peaked at $12.4M in Q1 2015. 189 funds tracked by Wall St. Rank hold IART as of Q3 2015.

Cramer Rosenthal McGlynn reported no remaining Integra LifeSciences position as of Q3 2015 after selling out during the quarter.
Cramer Rosenthal McGlynn sold 309,525 Integra LifeSciences shares in Q3 2015, an estimated $8.52M.
Cramer Rosenthal McGlynn first reported a position in Integra LifeSciences in Q4 2014 and held it in 3 quarters.
Cramer Rosenthal McGlynn's Integra LifeSciences position peaked at $12.4M in Q1 2015.
189 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2015.

Based on Cramer Rosenthal McGlynn's 13F filing for Q3 2015, filed 13 Nov 2015.